News

The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed clinical experiences with deep brain stimulation for atypical MS tremor and PD. [WATCH TIME: 5 minutes]

Research reveals that increased sedentary time significantly impacts neurodegeneration and cognitive decline in older adults, especially those genetically at risk for Alzheimer’s.

The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the link between iRBD and neurodegeneration.

The director of the Adult Genetic Epilepsy Program at the University of Toronto talked about how to ensure a smooth transition from pediatric to adult epilepsy care for university students. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending August 30, 2025. [WATCH TIME: 4 minutes]

The autoinjector, branded as Leqembi Iqlik, contains a 360 mg/1.8 mL dose administered over 15 seconds. It is expected to enhance Alzheimer treatment accessibility and offer cost savings for patients.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.

Long-term data confirms givinostat's safety and efficacy in delaying Duchenne muscular dystrophy progression, offering hope for patients and families.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health talked about prevention, understanding disease mechanisms, and creating a patient-centered care model in Parkinson disease. [WATCH TIME: 5 minutes]

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.

The head of the neurology department at the Vall d’Hebron University Hospital shared thoughts and perspectives on significance of fremanezumab’s recently expanded approval, calling it a long-awaited breakthrough for treating pediatric migraine. [WATCH TIME: 3 minutes]

Amylyx Pharmaceuticals discontinued its AMX0035 program for progressive supranuclear palsy after a phase 2b trial failed to show efficacy.

MediciNova's COMBAT-ALS trial reaches full enrollment, exploring ibudilast's potential to treat ALS and improve patient outcomes.

The neurophysiologist at Allegheny Health Network shared his clinical experience with tofersen in patients with SOD-1 ALS, while emphasizing the critical role of accessible genetic testing for patient identification. [WATCH TIME: 3 minutes]

A pivotal phase 3 study explores ampreloxetine's potential to treat neurogenic orthostatic hypotension in multiple system atrophy patients, aiming for FDA approval.

Merz initiates phase 3 trials for Xeomin, targeting migraine prevention in adults, aiming to fill gaps in current treatment options.

In a recent study, investigators developed multireceptor antagonist peptides that could block CGRP and PACAP, providing proof-of-concept for a potential new approach to targeting pathways involved in migraine.

Tracey Dawson, PhD, senior vice president of U.S. Therapeutic Area Head of Neuroscience at Novartis, expanded on the recently launched SMAshing My Limits campaign, a community-driven project aimed to address needs of developing teens with SMA.

The vice chair of education for the department of neurology at Mass General outlined her AUPN 2025 session on supporting clinician educators through recognition, career development, and institutional frameworks for advancement. [WATCH TIME: 4 minutes]

The head of the neurology department at Vall d’Hebron University Hospital provided clinical thoughts on fremanezumab’s expanded approval in pediatric migraine, the phase 3 SPACE study, and where future treatment may hold.

Spanning the United Kingdom, the United States, European Union, and Japan, the global phase 3 EMPEROR study of zorevunersen is expected to have a data readout by the end of 2027.

Serum NPTX2 emerges as a novel biomarker in ALS, with combined NPTX2 and NfL levels improving survival prediction and disease monitoring.

Regeneron's cemdisiran shows promising results in treating generalized myasthenia gravis, paving the way for a potential new drug application in 2026.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health highlighted the need for equitable, worldwide access to levodopa for patients with Parkinson disease. [WATCH TIME: 6 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.

The FDA has accepted the IND for COYA 302, a Treg-targeting combination therapy for ALS, clearing the way for a pivotal phase 2 multicenter trial.